Transformed Non-Hodgkin Lymphoma Clinical Trials

7 recruitingLast updated: June 18, 2026

There are 7 actively recruiting transformed non-hodgkin lymphoma clinical trials across 2 countries. Studies span Phase 2, Phase 1. Top locations include Eau Claire, Wisconsin, United States, New York, New York, United States, Columbus, Ohio, United States. Updated daily from ClinicalTrials.gov.


Transformed Non-Hodgkin Lymphoma Trials at a Glance

7 actively recruiting trials for transformed non-hodgkin lymphoma are listed on ClinicalTrialsFinder across 6 cities in 2 countries. The largest study group is Phase 2 with 6 trials, with the heaviest enrollment activity in Eau Claire, New York, and Columbus. Lead sponsors running transformed non-hodgkin lymphoma studies include City of Hope Medical Center, Malaghan Institute of Medical Research, and Aseel Alsouqi.

Browse transformed non-hodgkin lymphoma trials by phase

Treatments under study

About Transformed Non-Hodgkin Lymphoma Clinical Trials

Looking for clinical trials for Transformed Non-Hodgkin Lymphoma? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Transformed Non-Hodgkin Lymphoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Transformed Non-Hodgkin Lymphoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 1Phase 2

Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRefractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Diffuse Large B-Cell Lymphoma+11 more
Yazeed Sawalha38 enrolled2 locationsNCT06536049
Recruiting
Phase 1Phase 2

Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

Diffuse Large B Cell LymphomaHodgkin LymphomaMantle Cell Lymphoma+6 more
New York Medical College20 enrolled1 locationNCT04491370
Recruiting
Phase 2

A Study of WZTL-002 CAR T-cells for Adults With Relapsed Large B-cell Lymphoma

Large B-cell LymphomaPrimary Mediastinal Large B-cell Lymphoma (PMBCL)Diffuse Large B-Cell Lymphoma, Not Otherwise Specified+1 more
Malaghan Institute of Medical Research60 enrolled3 locationsNCT06486051
Recruiting
Phase 2

Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome

Recurrent Transformed Chronic Lymphocytic LeukemiaRefractory Transformed Chronic Lymphocytic LeukemiaTransformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma+5 more
Aseel Alsouqi24 enrolled3 locationsNCT05873712
Recruiting
Phase 1

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma

Diffuse Large B Cell LymphomaMantle Cell LymphomaB-cell Non Hodgkin Lymphoma+5 more
City of Hope Medical Center15 enrolled1 locationNCT05432635
Recruiting
Phase 2

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

Recurrent Grade 3b Follicular LymphomaRefractory Grade 3b Follicular LymphomaRecurrent Transformed Non-Hodgkin Lymphoma+28 more
Mayo Clinic41 enrolled7 locationsNCT06834373
Recruiting
Phase 2

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

High-grade B-cell LymphomaRecurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma+3 more
SWOG Cancer Research Network227 enrolled104 locationsNCT05890352